GlaxoSmithKline Pharmaceuticals presented to analysts and investors on November 6, 2025. Key highlights included a focus on commercial ambition driven by innovation, and a portfolio transformation driving profitability. The company reported revenue of ₹974cr with 34.4% EBITDA margin and 26.1% PAT margin. Key brands are competitive, with growth impacted by market headwinds.
Commercial Strategy
GSK India’s strategy is driven by focus and innovation, supported by cultural transformation. Key elements include:
- Focus: Sharper strategies for key brands to win versus competition.
- Agile: Adaptable approach to expand categories like adult immunization.
- Innovate: Scaling Oncology as the next frontier of innovation.
Financial Performance: Q2 FY25-26
The company reported the following key financials:
- Revenue:₹974cr (Growth -2.6%)
- EBITDA:₹335cr (Margin: 34.4%, Growth +4.9%)
- PAT:₹253cr (Margin: 26.1%, Growth +3.3%)
Despite a slight dip in revenue growth, EBITDA and PAT margins showed improvements.
Segment Highlights
Key highlights across different segments included:
- Pharma: Impacted by supply constraints and market dynamics.
- Specialty: Growth driven by Oncology product launches.
- Vaccines: Paediatric vaccines portfolio grew by 13%. Shingrix driven by strong partnerships.
Portfolio Transformation & Performance
The company’s portfolio transformation demonstrates competitive performance and improved profitability. Innovation across oncology and vaccines are key drivers.
Source: BSE
